Adrienne Fabrizio
Internal Medicine · Savannah, GANPI 1649219429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Pfizer at 24.3% of the total. Reporting peaked in 2019 at $994 and has fallen 93.8% since, to $62 in 2025.
Across 98 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$359
- AstraZeneca$202
- Amgen$197
- Dexcom, Inc.$103
- AbbVie$91
- Esperion Therapeutics, Inc.$76
- plus $450 from 11 others
What the payments were for
- Food & beverage$1,41696%
- Education$634%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $359 |
| AstraZeneca | 16 | $202 |
| Amgen | 12 | $197 |
| Dexcom, Inc. | 1 | $103 |
| AbbVie(2 entities) | 5 | $91 |
| Esperion Therapeutics, Inc. | 5 | $76 |
| Novo Nordisk | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Merck | 5 | $68 |
| Arbor Pharmaceuticals, Inc. | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Shire North American Group Inc | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Lilly USA, LLC | 2 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,479 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 13 | $1,731 |
| Duloxetine Hcl | 18 | $828 |
| Valsartan | 18 | $693 |
| ValacyclovirValacyclovir Hcl | 11 | $444 |
| Atorvastatin Calcium | 45 | $356 |
| Levothyroxine Sodium | 27 | $269 |
| Rosuvastatin Calcium | 28 | $247 |
| Famotidine | 17 | $189 |
| Escitalopram Oxalate | 14 | $125 |
| Zolpidem Tartrate | 16 | $93 |
| Fluoxetine Hcl | 13 | $85 |
| Omeprazole | 14 | $66 |
| Lisinopril | 14 | $61 |
| Amlodipine Besylate | 19 | $51 |
| Lorazepam | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $91 | $1,73113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Savannah
- Jennifer WoehlerSavannah$207K
- Timothy ConnellySavannah$50K
- John DemiccoSavannah$31K
- Paul BradleySavannah$28K
- Wilfredo DolorSavannah$17K
- Thomas HoganSavannah$17K
- Thomas MoriaritySavannah$16K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.